MCID: HYP082
MIFTS: 47

Hypopharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Hypopharynx Cancer

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 12 15 17
Hypopharyngeal Cancer 12 20 54 70
Malignant Neoplasm of Hypopharynx 12 32
Hypopharyngeal Neoplasms 44 70
Hypopharyngeal Carcinoma 17 70
Malignant Tumour of Hypopharynx 12
Malignant Hypopharyngeal Tumor 12
Malignant Tumor of Hypopharynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8533
ICD9CM 34 148 148.3
MeSH 44 D007012
NCIt 50 C7190
SNOMED-CT 67 93831006 93968005
ICD10 32 C13 C13.2 C13.9
UMLS 70 C0020627 C0153398 C0496770 more

Summaries for Hypopharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary : Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to oropharynx cancer and squamous cell papilloma. An important gene associated with Hypopharynx Cancer is MIR489 (MicroRNA 489), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include hypopharynx, lymph node and thyroid, and related phenotypes are integument and liver/biliary system

Related Diseases for Hypopharynx Cancer

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 30.5 TP53 EGFR CDKN2A CDH1
2 squamous cell papilloma 30.2 TP53 CDKN2A
3 larynx cancer 30.2 TP53 NME1 EGFR CDKN2A
4 esophageal cancer 30.1 TP53 EGFR CDKN2A CDH1 ALDH2 ADH1B
5 oral cancer 30.0 TP53 EGFR CDKN2A CDH1
6 in situ carcinoma 30.0 TP53 MIR142 EGFR CDKN2A CDH1
7 small cell cancer of the lung 30.0 TP53 EGFR CDKN2A
8 oral cavity cancer 30.0 MIR142 EGFR CDKN2A ALDH2
9 carcinosarcoma 29.8 TP53 EGFR CDKN2A CDH1
10 esophageal disease 29.8 TP53 MIR142 EGFR CDH1
11 nasopharyngeal carcinoma 29.7 TP53 NME1 MIR142 EGFR CDKN2A CDH1
12 squamous cell carcinoma 29.7 TP53 NME1 EGFR CDKN2A CDH1
13 laryngeal squamous cell carcinoma 29.6 TP53 NME1 LINC01537 EGFR CDKN2A CDH1
14 lung cancer susceptibility 3 29.6 TP53 MET EGFR CDKN2A CDH1
15 squamous cell carcinoma, head and neck 29.3 TP53 MIRLET7E MIR142 MET EGFR CDKN2A
16 malignant peritoneal mesothelioma 10.4 EGFR CDKN2A
17 doxorubicin induced cardiomyopathy 10.3 MET EGFR
18 papillary squamous carcinoma 10.3 EGFR CDKN2A
19 ovarian seromucinous carcinoma 10.3 TP53 CDKN2A
20 methanol poisoning 10.3 ALDH2 ADH1B
21 human papillomavirus infectious disease 10.3 TP53 CDKN2A
22 esophageal basaloid squamous cell carcinoma 10.3 TP53 EGFR
23 spitz nevus 10.3 TP53 CDKN2A
24 frontal lobe neoplasm 10.3 TP53 EGFR
25 avascular necrosis 10.3 ALDH2 ADH1B
26 peritoneal mesothelioma 10.3 MET EGFR CDKN2A
27 epstein-barr virus-associated gastric carcinoma 10.3 CDKN2A CDH1
28 bizarre leiomyoma 10.3 TP53 CDKN2A
29 spinal cord oligodendroglioma 10.3 TP53 EGFR
30 maxillary sinus benign neoplasm 10.3 CDKN2A CDH1
31 verrucous carcinoma 10.3 TP53 EGFR CDKN2A
32 sinus cancer 10.2
33 supraglottis cancer 10.2 TP53 EGFR CDKN2A
34 vulva squamous cell carcinoma 10.2 TP53 EGFR CDKN2A
35 bone squamous cell carcinoma 10.2 TP53 EGFR CDKN2A
36 adult malignant schwannoma 10.2 TP53 CDKN2A
37 soft tissue sarcoma 10.2 TP53 EGFR
38 laryngeal benign neoplasm 10.2 TP53 EGFR CDKN2A
39 vulvar disease 10.2 TP53 EGFR CDKN2A
40 peritoneum cancer 10.2 TP53 EGFR CDKN2A
41 anus cancer 10.2 TP53 EGFR CDKN2A
42 supratentorial cancer 10.2 TP53 EGFR CDKN2A
43 gliomatosis cerebri 10.2 TP53 EGFR CDKN2A
44 sarcomatoid transitional cell carcinoma 10.2 TP53 CDH1
45 breast malignant phyllodes tumor 10.2 TP53 EGFR
46 basaloid squamous cell carcinoma 10.2 TP53 EGFR CDKN2A
47 penile disease 10.2 TP53 EGFR CDKN2A
48 inverted papilloma 10.2 TP53 EGFR CDKN2A
49 mammary analogue secretory carcinoma 10.2 TP53 EGFR
50 suppressor of tumorigenicity 3 10.2 TP53 CDKN2A

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer

Symptoms & Phenotypes for Hypopharynx Cancer

MGI Mouse Phenotypes related to Hypopharynx Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.81 ALDH2 CDH1 CDKN2A CNDP2 EGFR ERCC6
2 liver/biliary system MP:0005370 9.61 ALDH2 CDKN2A CNDP2 EGFR ERCC6 MET
3 neoplasm MP:0002006 9.23 ALDH2 CDH1 CDKN2A EGFR ERCC6 MET

Drugs & Therapeutics for Hypopharynx Cancer

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4 Central Nervous System Stimulants Phase 4
5 Neurotransmitter Agents Phase 4
6 Cholinergic Agents Phase 4
7 Nicotinic Agonists Phase 4
8 Liver Extracts Phase 4
9 Antidepressive Agents Phase 4
10 Psychotropic Drugs Phase 4
11 Dopamine Agents Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Dopamine Uptake Inhibitors Phase 4
14
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
15
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
16
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
17 Muscarinic Agonists Phase 2, Phase 3
18 Tubulin Modulators Phase 3
19 Antimitotic Agents Phase 3
20 Albumin-Bound Paclitaxel Phase 3
21
Zinc Approved, Investigational Phase 2 7440-66-6 32051
22
Zinc oxide Approved Phase 2 1314-13-2
23
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
24 Raspberry Approved Phase 1, Phase 2
25
Fluorouracil Approved Phase 2 51-21-8 3385
26
nivolumab Approved Phase 2 946414-94-4
27
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
28
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
29
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
30
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
31
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
32
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
33 Immunosuppressive Agents Phase 2
34 Immunologic Factors Phase 2
35 Protective Agents Phase 2
36 Radiation-Protective Agents Phase 2
37 Zinc Supplement Phase 2
38 Dermatologic Agents Phase 2
39 Sunscreening Agents Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Cyclooxygenase 2 Inhibitors Phase 2
42 Analgesics Phase 2
43 Cyclooxygenase Inhibitors Phase 2
44 Antirheumatic Agents Phase 2
45 Anti-Inflammatory Agents Phase 2
46 Anti-Inflammatory Agents, Non-Steroidal Phase 2
47 Fluorides Phase 1, Phase 2
48 Fluorodeoxyglucose F18 Phase 1, Phase 2
49 Radiopharmaceuticals Phase 1, Phase 2
50 Arginyl-glycyl-aspartic acid Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
4 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
5 A Randomized Phase III Comparing Sequential Therapy With Induction Chemotherapy/Chemoradiation To Cisplatinum-Based Chemoradiotherapy in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT04502641 Phase 3 Docetaxel;5-fluorouracil;Cisplatin;Platinum
6 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
7 Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers Terminated NCT00128817 Phase 3
8 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
9 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
10 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
11 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
12 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
13 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
14 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
15 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
16 Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness Completed NCT00243113 Phase 2 docetaxel
17 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
18 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
19 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
20 New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT03558035 Phase 2 Induction CT+ CRT group
21 Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Recruiting NCT03894891 Phase 2 Nivolumab;Cisplatin;Docetaxel
22 A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT04156698 Phase 2 Docetaxel;Cisplatin;Capecitabine;Camrelizumab;Apatinib
23 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
24 Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study Not yet recruiting NCT04624308 Phase 2 Toripalimab
25 A Single-arm Study Evaluating Efficacy and Safety of Toripalimab Combined With Docetaxel and Cisplatin as Induced Chemotherapy in the Treatment of Localized Hypopharyngeal Squamous Cell Carcinoma Not yet recruiting NCT04296747 Phase 2 induction chemotherapy
26 Induction Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Cancer Not yet recruiting NCT04539600 Phase 2 Camrelizumab
27 Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT Terminated NCT01245985 Phase 2
28 A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT02113878 Phase 1 BKM120;Cisplatin
29 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
30 The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00174096
31 The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00302562
32 Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use Unknown status NCT00799669
33 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
34 The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Unknown status NCT00173381
35 Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer Patients: A Pilot Randomized Control Trial Completed NCT00797732
36 Computerized Scheduling of Nicotine Inhaler Use Completed NCT00021138 nicotine
37 Smoking Relapse Prevention Among Postpartum Women Completed NCT00310115
38 International Study of the Acceptability of Less Harmful Alternatives to Cigarettes (ISALHAC) - A Pilot Study Completed NCT00957424 nicotine replacement therapy
39 Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers Completed NCT00790569 nicotine;varenicline
40 Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers Completed NCT00533884
41 Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer Completed NCT03132727
42 A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery: A Prospective, Single Center, Multispecialty Study Completed NCT03010813
43 Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers Completed NCT01104714
44 Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery Completed NCT00473564
45 Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial Completed NCT03934294 Metoclopramide 10mg
46 A Multicenter OUS Post-Market Clinical Follow-Up of the Medrobotics Flex® Robotic System Used for Accessing and Visualizing the Oropharynx, Hypopharynx, and Larynx During Transoral Procedures Completed NCT02262247
47 Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA Completed NCT00534729 Weekly Carboplatin & Taxol w/concurrent RT
48 A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer Recruiting NCT02589938
49 Biomarkers and Dysplastic Respiratory Epithelium Recruiting NCT00900419
50 Phase III Study Assessing the "Best of" Radiotherapy Compared to the "Best of" Surgery (Trans-oral Surgery (TOS)) in Patients With T1-T2, N0-N1 Oropharyngeal, Supraglottic Carcinoma and With T1, N0 Hypopharyngeal Carcinoma Recruiting NCT02984410

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Genetic Tests for Hypopharynx Cancer

Anatomical Context for Hypopharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Hypopharynx Cancer:

19
Hypopharynx

MalaCards organs/tissues related to Hypopharynx Cancer:

40
Lymph Node, Thyroid, Skin, Liver, Tongue, Endothelial, Bone Marrow

Publications for Hypopharynx Cancer

Articles related to Hypopharynx Cancer:

(show top 50) (show all 1234)
# Title Authors PMID Year
1
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). 47
20700123 2010
2
[Expression of CD44 and nm23-H1 protein in the primary and metastatic lymph node lesions in supraglottic and hypopharyngeal cancer]. 61 54
16848180 2006
3
Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. 54 61
16308260 2006
4
Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. 61 54
9555115 1998
5
Health-Related Quality of Life Following Total Laryngectomy: A Systematic Review. 61
32866284 2021
6
Retrograde endoscopic submucosal dissection for early thoracic esophageal carcinoma. 61
33689125 2021
7
Evaluation of the usefulness of upper gastrointestinal endoscopy and the ValsamouthⓇ by an otolaryngologist in patients with Hypopharyngeal cancer. 61
32950326 2021
8
Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma. 61
33575927 2021
9
N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway. 61
33741902 2021
10
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. 61
32241084 2021
11
GPR12 inhibits migration and promotes apoptosis in esophageal cancer and hypopharyngeal cancer cells. 61
33742771 2021
12
Tumor dimension-dependent microscopic extensions of hypopharyngeal cancer: Therapeutic implications for larynx-preserving hypopharyngectomy. 61
33497489 2021
13
Risk of head and neck cancer in patients with peptic ulcers and the effect of Helicobacter pylori treatment. 61
33737604 2021
14
Letter to the editor "A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0". 61
33786657 2021
15
Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment. 61
33781050 2021
16
Analysis of palliative care treatment among head and neck patients with cancer: National perspective. 61
33151575 2021
17
Survival and function following pharyngo-laryngo-oesophagectomy in Wales: a twelve-year case series. 61
33509309 2021
18
Application of acellular dermal matrix to reconstruct the defects after hypopharyngeal carcinoma resection. 61
33352492 2021
19
Prediction of Disease Free Survival in Laryngeal and Hypopharyngeal Cancers Using CT Perfusion and Radiomic Features: A Pilot Study. 61
33681460 2021
20
Thoracoscopic total laryngo-pharyngo-oesophagectomy for the pharyngoesophageal junction cancer: a single-center experience of multidisciplinary team. 61
33651150 2021
21
Lung metastases in newly diagnosed hypopharyngeal cancer: a population-based study. 61
33599844 2021
22
Survival and complications with a surgical approach in advanced hypopharyngeal cancer. 61
33621353 2021
23
A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0. 61
33566179 2021
24
Improved Tumor Control Related to Radiotherapy Technological Development for Hypopharyngeal Cancer. 61
32396214 2021
25
Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis. 61
33652909 2021
26
The incidence of myocardial infarction and stroke in head and neck cancer patients. 61
33603026 2021
27
Modelling the number of avoidable new cancer cases in France attributable to alcohol consumption by following official recommendations: a simulation study. 61
33565659 2021
28
Simultaneous evaluation of symptoms, swallowing functions, and patient-reported swallowing difficulties and their correlations with ingestion status during definitive chemoradiotherapy for oropharyngeal and hypopharyngeal cancer. 61
32556716 2021
29
Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient. 61
33612350 2021
30
CD147 promotes invasion and MMP-9 expression through MEK signaling and predicts poor prognosis in hypopharyngeal squamous cell carcinoma. 61
33529506 2021
31
Early Mortality after Radical Radiotherapy in Head and Neck Cancer - A Nationwide Analysis from the Danish Head and Neck Cancer Group (DAHANCA) Database. 61
32698963 2021
32
Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. 61
33469045 2021
33
High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer. 61
33777804 2021
34
Using the larynx as a last resort for oral intake in a hypopharyngeal cancer patient. 61
33455818 2021
35
To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer? 61
33648773 2021
36
Hypopharyngeal reconstruction with gastro-omental free flap. 61
33431349 2021
37
The incidence of newly diagnosed secondary cancer; sub-analysis the prospective study of the second-look procedure for transoral surgery in patients with T1 and T2 head and neck cancer. 61
32929629 2021
38
3-MA Enhanced Chemosensitivity in Cisplatin Resistant Hypopharyngeal Squamous Carcinoma Cells via Inhibiting Beclin -1 Mediated Autophagy. 61
33349212 2020
39
Design and application of submental island flap to reconstruct non-circumferential defect after hypopharyngeal carcinoma resection: a prospective study of 27 cases. 61
32808843 2020
40
Value of oesophagoscopy and bronchoscopy in diagnosis of synchronous malignancies in patients with head and neck squamous cell carcinomas. 61
33256662 2020
41
[Correctly understanding, scientifically evaluating, and actively promoting standardized treatment of hypopharyngeal cancer]. 61
33342125 2020
42
ASO Author Reflections: Salvage Total Laryngectomy, the Last Resort for Patients with Residual, Recurrent or Second Primary Laryngeal and Hypopharyngeal Cancer in Times of Nonsurgical Organ Preserving Treatment Strategies. 61
32851516 2020
43
Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation. 61
33385465 2020
44
Human Bone Marrow Mesenchymal Stem Cells Modified Hybrid Baculovirus-Adeno-Associated Viral Vectors Targeting 131I Therapy of Hypopharyngeal Carcinoma. 61
32940055 2020
45
[Application of rigid curved laryngoscope in the examination of hypopharynx and the treatment of early hypopharyngeal cancer]. 61
33342129 2020
46
Effect of Periodontitis and Scaling and Root Planing on Risk of Pharyngeal Cancer: A Nested Case-Control Study. 61
33375028 2020
47
Simultaneous Endoscopic Resection of Superficial Cancers of the Hypopharynx and Esophagus: A Case Report. 61
32475899 2020
48
[Carotid-subclavian Bypass for Radiation-induced Subclavian Artery Occlusion;Report of a Case]. 61
33271578 2020
49
Predictors of Weight Loss in Patients With Head and Neck Cancer Receiving Radiation or Concurrent Chemoradiation Treated at a Tertiary Cancer Center. 61
32329543 2020
50
Vascular events from carotid artery atherosclerosis after radiation therapy for laryngeal and hypopharyngeal cancer: the incidence and risk factors. 61
33311805 2020

Variations for Hypopharynx Cancer

Expression for Hypopharynx Cancer

Search GEO for disease gene expression data for Hypopharynx Cancer.

Pathways for Hypopharynx Cancer

Pathways related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 12.62 TP53 MET EGFR CDKN2A CDH1
2
Show member pathways
12.52 TP53 MET EGFR CDKN2A CDH1
3
Show member pathways
12.4 TP53 MET EGFR CDKN2A CDH1
4
Show member pathways
12.23 TP53 NGFR MET EGFR
5 12.15 TP53 MIRLET7E MET EGFR CDKN2A
6
Show member pathways
11.68 MET EGFR CDH1
7 11.5 MET EGFR CDH1
8 11.45 TP53 MET EGFR
9 11.25 TP53 EGFR CDKN2A
10 11.1 MET EGFR CDH1
11 10.85 TP53 MIRLET7E EGFR
12 10.79 TP53 EGFR CDKN2A CDH1
13
Show member pathways
10.73 ALDH2 ADH1B
14
Show member pathways
10.72 ALDH2 ADH1B
15 10.64 NME1 ADH1B
16 10.62 MET EGFR CDH1

GO Terms for Hypopharynx Cancer

Biological processes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 circadian rhythm GO:0007623 9.33 TP53 NGFR EGFR
2 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.32 TP53 EGFR
3 ethanol oxidation GO:0006069 9.26 ALDH2 ADH1B
4 cellular response to drug GO:0035690 9.13 TP53 NME1 EGFR
5 entry of bacterium into host cell GO:0035635 8.62 MET CDH1

Molecular functions related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 TP53 MET EGFR
2 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A

Sources for Hypopharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....